MX2018013701A - Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3. - Google Patents
Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.Info
- Publication number
- MX2018013701A MX2018013701A MX2018013701A MX2018013701A MX2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- pyridinyl derivatives
- aoc3 inhibitors
- aoc3
- inhibitors
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004076 pyridyl group Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a nuevos derivados de piridinilo de la fórmula (I) (VER FORMULA) en donde R1 y A son como se definen en la descripción y las reivindicaciones, a su uso como medicamentos, a los métodos para su uso terapéutico y a las composiciones farmacéuticas que los contienen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169356 | 2016-05-12 | ||
| PCT/EP2017/060890 WO2017194453A1 (en) | 2016-05-12 | 2017-05-08 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013701A true MX2018013701A (es) | 2019-05-02 |
| MX379327B MX379327B (es) | 2025-03-11 |
Family
ID=55967162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013701A MX379327B (es) | 2016-05-12 | 2017-05-08 | Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9926292B2 (es) |
| EP (1) | EP3455216B1 (es) |
| JP (1) | JP6639702B2 (es) |
| KR (1) | KR20190003995A (es) |
| CN (1) | CN109153664B (es) |
| AR (1) | AR108462A1 (es) |
| AU (1) | AU2017262707B2 (es) |
| CA (1) | CA3023805A1 (es) |
| CL (1) | CL2018003158A1 (es) |
| CO (1) | CO2018012020A2 (es) |
| CY (1) | CY1123744T1 (es) |
| DK (1) | DK3455216T3 (es) |
| EA (1) | EA037188B1 (es) |
| ES (1) | ES2844926T3 (es) |
| HR (1) | HRP20202078T1 (es) |
| HU (1) | HUE053312T2 (es) |
| IL (1) | IL262662B (es) |
| JO (1) | JOP20170115B1 (es) |
| LT (1) | LT3455216T (es) |
| MA (1) | MA44965B1 (es) |
| MX (1) | MX379327B (es) |
| PE (1) | PE20190151A1 (es) |
| PH (1) | PH12018502376B1 (es) |
| PL (1) | PL3455216T3 (es) |
| PT (1) | PT3455216T (es) |
| RS (1) | RS61256B1 (es) |
| SA (1) | SA518400393B1 (es) |
| SG (1) | SG11201809687TA (es) |
| SI (1) | SI3455216T1 (es) |
| TW (1) | TWI746551B (es) |
| UA (1) | UA121930C2 (es) |
| WO (1) | WO2017194453A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019254371A1 (en) * | 2018-04-17 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN112789277B (zh) * | 2018-10-22 | 2022-11-04 | 广东东阳光药业有限公司 | 胍类衍生物及其用途 |
| CN112955214B (zh) | 2018-10-29 | 2024-05-07 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| FI3873600T3 (fi) | 2018-10-29 | 2023-12-07 | Boehringer Ingelheim Int | Pyridinyylisulfonamidijohdannaisia, farmaseuttisia koostumuksia ja niiden käytöt |
| EP4051669A4 (en) | 2019-10-29 | 2023-12-13 | Eccogene (Shanghai) Co., Ltd. | SSAO INHIBITORS AND THEIR USE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19518073A1 (de) * | 1995-05-17 | 1996-11-21 | Hoechst Ag | Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| JP5010917B2 (ja) * | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| WO2006011631A2 (en) * | 2004-07-27 | 2006-02-02 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
| CA2772689A1 (en) * | 2009-09-16 | 2011-03-24 | Astellas Pharma Inc. | Glycine compound |
| PT3002278T (pt) * | 2011-03-15 | 2017-06-29 | Astellas Pharma Inc | Composto de guanidina |
| JP6809464B2 (ja) | 2015-08-06 | 2021-01-06 | 宇部興産株式会社 | 置換グアニジン誘導体 |
-
2017
- 2017-05-08 US US15/588,739 patent/US9926292B2/en active Active
- 2017-05-08 JP JP2018559351A patent/JP6639702B2/ja active Active
- 2017-05-08 WO PCT/EP2017/060890 patent/WO2017194453A1/en not_active Ceased
- 2017-05-08 PE PE2018002340A patent/PE20190151A1/es unknown
- 2017-05-08 HR HRP20202078TT patent/HRP20202078T1/hr unknown
- 2017-05-08 CA CA3023805A patent/CA3023805A1/en active Pending
- 2017-05-08 CN CN201780027576.9A patent/CN109153664B/zh active Active
- 2017-05-08 SI SI201730584T patent/SI3455216T1/sl unknown
- 2017-05-08 LT LTEP17721706.4T patent/LT3455216T/lt unknown
- 2017-05-08 HU HUE17721706A patent/HUE053312T2/hu unknown
- 2017-05-08 DK DK17721706.4T patent/DK3455216T3/da active
- 2017-05-08 PT PT177217064T patent/PT3455216T/pt unknown
- 2017-05-08 AU AU2017262707A patent/AU2017262707B2/en not_active Ceased
- 2017-05-08 KR KR1020187035976A patent/KR20190003995A/ko not_active Abandoned
- 2017-05-08 SG SG11201809687TA patent/SG11201809687TA/en unknown
- 2017-05-08 MX MX2018013701A patent/MX379327B/es unknown
- 2017-05-08 MA MA44965A patent/MA44965B1/fr unknown
- 2017-05-08 RS RS20201583A patent/RS61256B1/sr unknown
- 2017-05-08 UA UAA201812102A patent/UA121930C2/uk unknown
- 2017-05-08 EP EP17721706.4A patent/EP3455216B1/en active Active
- 2017-05-08 ES ES17721706T patent/ES2844926T3/es active Active
- 2017-05-08 EA EA201892539A patent/EA037188B1/ru not_active IP Right Cessation
- 2017-05-08 PL PL17721706T patent/PL3455216T3/pl unknown
- 2017-05-11 AR ARP170101262A patent/AR108462A1/es not_active Application Discontinuation
- 2017-05-11 TW TW106115558A patent/TWI746551B/zh not_active IP Right Cessation
- 2017-05-11 JO JOP/2017/0115A patent/JOP20170115B1/ar active
-
2018
- 2018-10-29 IL IL262662A patent/IL262662B/en unknown
- 2018-11-06 CO CONC2018/0012020A patent/CO2018012020A2/es unknown
- 2018-11-07 SA SA518400393A patent/SA518400393B1/ar unknown
- 2018-11-08 CL CL2018003158A patent/CL2018003158A1/es unknown
- 2018-11-12 PH PH12018502376A patent/PH12018502376B1/en unknown
-
2021
- 2021-01-19 CY CY20211100039T patent/CY1123744T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800132A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UY35467A (es) | Compuestos orgánicos | |
| MX389349B (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| CL2017003107A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| ECSP21030482A (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
| BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| MX2016016583A (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| MX2017006536A (es) | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. | |
| CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| MX2016005142A (es) | Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35876A (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| ECSP18056196A (es) | Derivados de indano | |
| CO2017002963A2 (es) | Espiro-tiazolonas |